Exsight
Emerging managerBuilt from this firm's Form D filings. The firm files no SEC adviser report.
- HQ
- NY
ExSight is a venture firm that describes itself as a leading early-stage ophthalmic investor. Its portfolio includes Novai, a British biotech startup working on an AI-supported retinal biomarker for glaucoma and AMD trials, and DefEYE, which uses decellularized placental tissue for ocular surface disease and surgical management. The firm also increased its ophthalmology-focused Fund 3 by 60%, with participation from a leading eye care foundation.
01 · Says / Does
| Tag | Says | Does |
|---|---|---|
| Stages | Not stated | Not enough dated deals |
| Sectors | Not stated | Not enough dated deals |
| Regions | Not stated | Not enough dated deals |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| ExSight Fund IV, LLC | 2024 | $4.15M to $15M (Form D) | Open, writing first checks |
03 · People across funds
- James Murray, Executive officer of the managing member of the Issuer
ExSight Fund IV, LLC (Named on Form D)
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://www.exsightventures.com
- https://www.exsightventures.com/contact
- https://www.exsightventures.com/
- https://www.exsightventures.com/blog
- https://www.exsightventures.com/portfolio
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 25, 2026